Clinical and MRI Findings in Patients with SLC19A3 Mutations
Author Information
Author(s): Yamada Kenichiro, Miura Kiyokuni, Hara Kenju, Suzuki Motomasa, Nakanishi Keiko, Kumagai Toshiyuki, Ishihara Naoko, Yamada Yasukazu, Kuwano Ryozo, Tsuji Shoji, Wakamatsu Nobuaki
Primary Institution: Institute for Developmental Research, Aichi Human Service Center, Aichi, Japan
Hypothesis
What are the clinical and brain MRI findings associated with SLC19A3 mutations?
Conclusion
The study broadens the phenotypic spectrum of disorders associated with SLC19A3 mutations and highlights the need to assess the efficacy of biotin and/or thiamin treatments.
Supporting Evidence
- A homozygous mutation (c.958G > C, [p.E320Q]) in SLC19A3 was identified in all four patients.
- Administration of a high dose of biotin for one year did not improve neurological symptoms in one patient.
- Patients presented with epileptic spasms in early infancy and severe psychomotor retardation.
Takeaway
This study looked at four patients with a specific gene mutation and found that they had similar brain problems and symptoms, but treatments didn't help them get better.
Methodology
Detailed clinical, brain MRI, and molecular genetic analysis of four Japanese patients.
Limitations
The efficacy of high doses of biotin and/or thiamin for the clinical phenotypes of the patients has not been determined.
Participant Demographics
Four Japanese patients from a consanguineous family.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website